BR0213249A - Dispositivo e eletrodo para a aplicação ocular de um princìpio ativo - Google Patents

Dispositivo e eletrodo para a aplicação ocular de um princìpio ativo

Info

Publication number
BR0213249A
BR0213249A BR0213249-4A BR0213249A BR0213249A BR 0213249 A BR0213249 A BR 0213249A BR 0213249 A BR0213249 A BR 0213249A BR 0213249 A BR0213249 A BR 0213249A
Authority
BR
Brazil
Prior art keywords
electrode
active principle
ocular application
eye
application
Prior art date
Application number
BR0213249-4A
Other languages
English (en)
Inventor
Francine Behar
Pierre Roy
Original Assignee
Optis France S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optis France S A filed Critical Optis France S A
Publication of BR0213249A publication Critical patent/BR0213249A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/0436—Material of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Electrotherapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"DISPOSITIVO E ELETRODO PARA A APLICAçãO OCULAR DE UM PRINCìPIO ATIVO". Dispositivo de aplicação ocular de um princípio ativo (1) que compreende um eletrodo principal (2) que possui uma camada isolante, uma camada de adesivo própria para ligar a camada isolante a uma camada condutora, caracterizado pelo fato de que o eletrodo principal apresenta uma zona (21, 22) própria para entrar em contato com uma pálpebra de um olho.
BR0213249-4A 2001-10-12 2002-10-11 Dispositivo e eletrodo para a aplicação ocular de um princìpio ativo BR0213249A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0113176A FR2830766B1 (fr) 2001-10-12 2001-10-12 Dispositif de delivrance de medicaments par iontophorese transpalpebrale
PCT/FR2002/003472 WO2003030989A2 (fr) 2001-10-12 2002-10-11 Dispositif de delivrance de medicaments par iontophorese transpalpebrale

Publications (1)

Publication Number Publication Date
BR0213249A true BR0213249A (pt) 2004-09-28

Family

ID=8868226

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213249-4A BR0213249A (pt) 2001-10-12 2002-10-11 Dispositivo e eletrodo para a aplicação ocular de um princìpio ativo

Country Status (16)

Country Link
US (3) US7848800B2 (pt)
EP (1) EP1434622B1 (pt)
JP (1) JP4184275B2 (pt)
KR (1) KR20050035158A (pt)
AT (1) ATE358510T1 (pt)
BR (1) BR0213249A (pt)
CA (1) CA2463362C (pt)
CY (1) CY1106671T1 (pt)
DE (1) DE60219336T2 (pt)
DK (1) DK1434622T3 (pt)
ES (1) ES2283628T3 (pt)
FR (1) FR2830766B1 (pt)
IL (1) IL161298A0 (pt)
MX (1) MXPA04003438A (pt)
PT (1) PT1434622E (pt)
WO (1) WO2003030989A2 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090088721A1 (en) * 2001-04-17 2009-04-02 Eyegate Pharma S.A.S. Enhanced retinal delivery of a nucleic acid through iontophoresis
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
FR2869531B1 (fr) * 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
AU2005247122C1 (en) 2004-04-30 2012-02-02 Eyegate Pharma S.A. Irritation-reducing ocular iontophoretic device
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20060089590A1 (en) * 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
US8755880B2 (en) 2005-10-24 2014-06-17 Aciont, Inc. Intraocular iontophoretic device and associated methods
US20070260171A1 (en) * 2005-09-27 2007-11-08 Higuchi John W Intraocular iontophoretic device and associated methods
US8634907B2 (en) 2005-10-24 2014-01-21 Aciont, Inc. Intraocular iontophoretic device and associated methods
JP5128932B2 (ja) * 2007-12-28 2013-01-23 日立マクセル株式会社 美容機器
MX2011006925A (es) 2008-12-31 2011-07-28 Eyegate Pharma S A S Sistema y metodo de iontoforesis ocular con amortiguacion.
CA2755773A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411520A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
MX2011010072A (es) 2009-03-27 2011-10-06 Merck Sharp & Dohme Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen de la molecula de adhesion intercelular 1 usando acido nucleico corto de interferencia.
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
JP2011018873A (ja) * 2009-05-22 2011-01-27 Sony Ericsson Mobilecommunications Japan Inc 電磁シールド方法および電磁シールド用フィルム
WO2012004416A2 (en) 2010-07-09 2012-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of a disease associated with retinal degenerative disorder
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9233997B2 (en) 2010-08-26 2016-01-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP2016507484A (ja) 2012-12-06 2016-03-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ジスルフィドマスキングプロドラッグ組成物および方法
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US9937074B2 (en) 2015-01-22 2018-04-10 Eyegate Pharmaceuticals, Inc. Iontophoretic contact lens
US20180125947A1 (en) 2015-05-20 2018-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of retinal detachment
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
BR112019012045A2 (pt) 2016-12-13 2020-08-18 Beta Therapeutics Pty Ltd inibidores de heparanase e uso dos mesmos
IT201700014315A1 (it) * 2017-02-09 2018-08-09 Bruno Massimo Cetroni Dispositivo per il trasporto intracellulare in biorisonanza
KR101889357B1 (ko) * 2017-09-20 2018-08-17 (주)휴비딕 눈의 나노 약물 전달용 이온공급 장치
EP3823567B1 (en) * 2018-07-20 2025-06-18 The USA, as represented by The Secretary, Department of Health and Human Services Intraocular injection of gene therapy expression vectors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845757A (en) * 1972-07-12 1974-11-05 Minnesota Mining & Mfg Biomedical monitoring electrode
US4564016A (en) * 1982-05-24 1986-01-14 The Board Of Trustees Of The Leland Stanford Junior University Apparatus for introducing ionized drugs into the posterior segment of the eye and method
US4603076A (en) * 1985-03-04 1986-07-29 Norwood Industries, Inc. Hydrophilic foam
US5320597A (en) * 1991-02-08 1994-06-14 Becton, Dickinson And Company Device and method for renewing electrodes during iontophoresis
US5169384A (en) * 1991-08-16 1992-12-08 Bosniak Stephen L Apparatus for facilitating post-traumatic, post-surgical, and/or post-inflammatory healing of tissue
US5356632A (en) * 1991-09-12 1994-10-18 S.I. Scientific Innovations Ltd. Transdermal drug delivery device
AU652494B2 (en) * 1991-11-15 1994-08-25 Minnesota Mining And Manufacturing Company Solid state conductive polymer compositions, biomedical electrodes containing such compositions, and method of preparing same
US5450845A (en) * 1993-01-11 1995-09-19 Axelgaard; Jens Medical electrode system
US5522864A (en) * 1994-10-25 1996-06-04 Wallace; Larry B. Apparatus and method for ocular treatment
AUPM982694A0 (en) * 1994-12-02 1995-01-05 University Of Queensland, The Iontophoresis method and apparatus
FR2773320B1 (fr) * 1998-01-05 2000-03-03 Optisinvest Dispositif pour le transfert intraoculaire de produits actifs par iontophorese
IL123290A (en) * 1998-02-13 2001-12-23 Hadasit Med Res Service Iontophoretic device
US6503231B1 (en) * 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US6277401B1 (en) * 1999-05-07 2001-08-21 U.S. Dermatologics, Inc. Drug delivery device
US6728573B1 (en) * 2000-02-23 2004-04-27 Iomed, Inc. Ocular iontophoretic apparatus handle
US6697668B2 (en) * 2001-01-25 2004-02-24 Iomed, Inc. Ocular iontophoretic device and method for using the same
US6546284B2 (en) * 2001-01-25 2003-04-08 Iomed, Inc. Fluid retention assembly for an iontophoretic delivery device and associated method for preparing the same
US20040106965A1 (en) * 2001-06-29 2004-06-03 Chow Alan Y. Methods and apparatus for treatment of degenerative retinal disease via indirect electrical stimulation
US20030023228A1 (en) * 2001-07-20 2003-01-30 Parkinson Thomas M. Ocular iontophoretic device and method for using the same
US6694193B2 (en) * 2001-09-14 2004-02-17 Koninklijke Philips Electronics N.V. Medical electrode and release liner configurations facilitating packaged electrode characterization

Also Published As

Publication number Publication date
ATE358510T1 (de) 2007-04-15
US8771256B2 (en) 2014-07-08
JP2005504612A (ja) 2005-02-17
US20140323947A1 (en) 2014-10-30
US9192512B2 (en) 2015-11-24
PT1434622E (pt) 2007-07-11
CY1106671T1 (el) 2012-05-23
DK1434622T3 (da) 2007-08-13
CA2463362A1 (fr) 2003-04-17
WO2003030989A2 (fr) 2003-04-17
MXPA04003438A (es) 2005-02-17
KR20050035158A (ko) 2005-04-15
EP1434622B1 (fr) 2007-04-04
US20040267188A1 (en) 2004-12-30
WO2003030989A3 (fr) 2003-10-30
CA2463362C (fr) 2011-04-19
IL161298A0 (en) 2004-09-27
ES2283628T3 (es) 2007-11-01
FR2830766A1 (fr) 2003-04-18
US20110098632A1 (en) 2011-04-28
JP4184275B2 (ja) 2008-11-19
US7848800B2 (en) 2010-12-07
DE60219336T2 (de) 2007-12-20
EP1434622A2 (fr) 2004-07-07
DE60219336D1 (de) 2007-05-16
FR2830766B1 (fr) 2004-03-12

Similar Documents

Publication Publication Date Title
ATE358510T1 (de) Vorrichtung zur iontophoretischen verabreichung von medikamenten durch das augenlid
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
BR0116037A (pt) Soluções de acondicionamento de lentes de contato
BR0214368A (pt) Substrato vìtreo, utilização do substrato e célula solar
BR0317872A (pt) Medicamentos antiinflamatórios
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
BR0106967A (pt) Dispositivo de acondicionamento e/ou de aplicação que contém fibras que possuem pelo menos um corpo imantado ou imantável
ATE234092T1 (de) 2-alkylpyrrolidine
BR0213012A (pt) Lentes eletro-ativas hìbridas
BR0017149B1 (pt) curativo mÉdico possuindo superfÍcies de topo e de fundo.
FR2864526B1 (fr) Dispositif d'actionnement electrostatique
ES2140660T3 (es) Sistema de gestion de transacciones controlado por un circuito integrado.
ECSP044862A (es) Pirenzepine ophthalmic gel
MXPA04005007A (es) Prenda absorbente con ingredientes para bienestar de la piel incorporados.
AR020338A1 (es) Lentes de contacto estabilizados dinamicamente
BR0202111A (pt) Dispositivo para a aplicação de um produto de bronzeamento artificial sobre a pele, kit e processo de fabricação de um tal dispositivo
NO20011427D0 (no) Anordning for akupressurisk behandling
BRPI0203743B8 (pt) curativo adesivo.
BR0314787A (pt) Forma de dosagem de liberação modificada
BR0306662A (pt) Formulação lacrimal de três camadas
ES2164322T3 (es) Dispositivo de conmutacion para conexiones entre circuitos electricos.
DE60226076D1 (de) Kühlungseinrichtung mit direkter kühlung von aktiven elektronischen komponenten
HRP20031057B1 (hr) Tableta koja sadrži cetirizin i pseudoefedrin
BR0116781A (pt) Dispositivo absorvente interlabial
BR9914012A (pt) Dispositivo para o tratamento de lentes de contato

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: EYEGATE PHARMA S.A. (FR)

Free format text: ALTERADO DE: OPTIS FRANCE S.A.

B25G Requested change of headquarter approved

Owner name: EYEGATE PHARMA S.A. (FR)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020060112495/RJ DE 25/07/2006.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements